Whooping cough vaccines: Where next?

Child: Care, Health and Development

Volumn 24, Issue 4, 1998, Pages 259-267

  Elliman, D ^a,b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b Great Ormond Street Hospital for Children   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; IMMUNIZATION; INFANT; MORTALITY; PERTUSSIS; PRESCHOOL CHILD; REVIEW; UNITED KINGDOM;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; GREAT BRITAIN; HUMANS; IMMUNIZATION SCHEDULE; INFANT; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 0032112330     PISSN: 03051862     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2214.1998.tb00945.x     Document Type: Article

References (18)

1. Ad hoc group for the study of pertussis vaccines (1988) Placebo-controlled trial of two acellular pertussis vaccines in Sweden-Protective efficacy and adverse events. Lancet i, 955-960.
2. Anonymous (1997) Pertussis vaccine trials. Developments in Biological Standardization Volume 89. Karger, Basel.
3. Brody, M. & Sorley, R.G. (1947) Neurologic complications following administration of pertussis vaccine. New York State Journal of Medicine 47, 1016-17.
4. The Committee on Safety of Medicines and the Joint Committee on Vaccination and Immunization (1984) Whooping Cough. London, DHSS, HMSO.
5. Davies, E., Elliman, D., Hart, C., Nicoll, A. & Rudd, P. (eds) (1996) Manual of Childhood Infections. WB Saunders, London.
6. Farrington, P., Pugh, S., Colville, A., Flower, A., Nash, J., Morgan-Caprier, P., Rush, M. & Miller, E. (1995) A new method for active surveillance of adverse events from diphtheria/tetanus/ pertussis and measles/mumps/rubella vaccines. Lancet, 345, 567-569.
7. Gangarosa, E., Galazka, A., Wolfe, C., Phillips, L., Gangarosa, R., Miller, E. & Chen, R. (1998) Impact of antivaccine movements on pertussis control: the untold story. Lancet 351, 356-361.
8. Kimura, M. & Kuno-Sakai, H. (1988) Pertussis vaccines in Japan. Acta Paediatrica Japonica 30, 143-153.
9. Miller, E., Ashworth, L., Redhead, K., Thornton, C., Wraight, P. & Coleman, T. (1997) Effect of schedule on acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine 15, 51-60.
10. Miller, E. & Eskola, J. (1998) Issues about pertussis vaccines. Lancet 351, 677-678.
11. Nennig, M., Shinefield, H., Edwards, K., Black, S. & Fireman, B. (1996) Prevalence and incidence of adult pertussis in an urban population. Journal of the American Medical Association 275, 1672-74.
12. Olin, P., Rasmussen, F., Gustafsson, L., Hallander, H. & Heijbel, H. (1997) for the Ad Hoc Group for the Study of Pertussis Vaccines. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350, 1569-77.
13. Plotkin, S. & Cadoz, M. (1997a) The acellular pertussis vaccine trials: an interpretation. Pediatric Infectious Diseases Journal 16, 508-517.
14. Plotkin, S.A. & Cadoz, M. (1997b) Acellular vaccine efficacy trials. Pediatric Infectious Diseases Jaurnal 16, 913-914.
15. Poland, G.A. (1997) Still more questions on pertussis vaccines. Lancet 350, 1564-65.
16. Schneerson, R., Robbins, J., Taranger, J., Lagergard, T. & Trollfors, B. (1996) A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet 348, 1289-92.
17. Stuart-Smith, S. Judgement in Loveday vs Renton & Wellcome. Royal Courts of Justice, London, March 29-30, 1988.
18. Vermeer-de Bondt, P.E., Labadie, J. & Rumke, H.C. (1998) Rate of recurrent collapse after vaccination with whole cell vaccine. BMJ 316, 902-903.